Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Enclomiphene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 11/20 | 1.00 |
| ▸ | EBP | Q15125 | 6/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 3/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 3/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 3/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 3/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 1.00 |
| ▸ | DRD3 | P35462 | 3/20 | 1.00 |
| ▸ | HTR6 | P50406 | 3/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enclomiphene SCHEMBL34893 | 1.00 | ESR1 (1.00) | ESR1EBPKMT2ASIGMAR1CYP2D6 | |
| Zuclomiphene SCHEMBL34894 | 1.00 | ESR1 (1.00) | ESR1EBPKMT2ASIGMAR1CYP2D6 | |
| Enclomiphene SCHEMBL20594021 | 1.00 | ESR1 (1.00) | ESR1EBPKMT2ASIGMAR1CYP2D6 | |
| Clomiphene SCHEMBL29379763 | 1.00 | ESR1 (1.00) | ESR1EBPKMT2ASIGMAR1CYP2D6 | |
| SCHEMBL10407739 | 1.00 | ESR1 (1.00) | ESR1EBPKMT2ASIGMAR1CYP2D6 | |
| Enclomiphene SCHEMBL407458 | 0.99 | ESR1 (0.97) | ESR1EBPKMT2ASIGMAR1CYP2D6 | |
| Clomiphene SCHEMBL27689011 | 0.99 | ESR1 (0.97) | ESR1EBPKMT2ASIGMAR1CYP2D6 | |
| Zuclomiphene SCHEMBL402392 | 0.99 | ESR1 (0.97) | ESR1EBPKMT2ASIGMAR1CYP2D6 | |
| Zuclomiphene SCHEMBL23357662 | 0.95 | ESR1 (0.90) | ESR1EBPKMT2ASIGMAR1CYP2D6 | |
| 4-Oh-Enclomiphene SCHEMBL17152123 | 0.95 | ESR1 (0.90) | ESR1EBPKMT2ASIGMAR1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008133884-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-11-06 | — | — | WO | disclosed |
| US-4310523-A | Combined antiestrogens and antigonadotropically effective antiandrogens for the prophylaxis and therapy of hyperplasia of the prostate | SCHERING AKTIENGESELLSCHAFT (DE) | 1982-01-12 | — | — | US | disclosed |